This study revealed that topiroxostat use not only reduced the serum uric acid level but also maintained renal function in elderly patients with hyperuricemia in daily clinical practice. The estimated glomerular filtration rate significantly decreased during the 6 months before topiroxostat administration (p < 0.001), but showed no significant change at 6 months after topiroxostat administration (p = 0.849). After 12 months, the serum creatinine level and estimated glomerular filtration rate showed no significant changes from baseline however, the serum uric acid level significantly decreased. Forty-four patients administered uric acid-lowering drugs were switched to topiroxostat. The study mainly involved elderly individuals (77.2 ± 9.5 years). The secondary endpoints were changes in serum creatinine, serum uric acid, and estimated glomerular filtration rate before and after topiroxostat administration. The primary endpoints were changes in serum creatinine level and estimated glomerular filtration rate at 12 months after topiroxostat administration. From the medical records, data of 100 patients with hyperuricemia treated with topiroxostat were extracted (67:33 male:female). Medical records of patients from 1 January, 2015 to 31 October, 2019 in our hospital were used. We aimed to retrospectively evaluate renal function and serum uric acid in patients with hyperuricemia who received topiroxostat for over a year. Serum uric acid-lowering therapy is associated with maintaining renal function. This study demonstrates neither a strong significant association between SUA and rapid decline of eGFR nor evidence to refuse the role of SUA levels in the increased risk of renal function decline in in T2DM patients. However, the association between tertiles of SUA and rapid decline of eGFR was not statistically significant. This association was marginally significant when more covariates were included in the model (OR = 1.20, 95% CI 0.99–1.46, p = 0.065). After adjusting for age and sex, rapid progression of renal function was significantly associated with SUA level (OR = 1.22, 95% CI 1.02–1.45, p = 0.026). Patients in the SUA high tertile ( ≥6 mg/dL) had higher BMI (p = 0.004), lower HbA1c (p = 0.001), lower eGFR (p < 0.001) and higher rate of hypertension than low and middle tertile. Rapid progression of kidney function was defined as an average annual decrease of eGFR of at least 4 mL/min/1.73 m2 and was found in 16.0% of patients. We followed 405 T2DM patients with normal kidney function for five years. A prospective cohort study was conducted in a community-based hospital in Vietnam. This study investigated the association between serum uric acid (SUA) levels with rapid decline of the estimated glomerular filtration rate (eGFR) in type 2 diabetes (T2 DM) patients. In comparison, greater uric acid levels had a significant, but much weaker, association with progression of kidney disease. Uric acid levels are associated strongly with prevalent CKD. Measurements of albuminuria were not available. No significant association was found between uric acid level and incident CKD (adjusted odds ratio, 1.00 95% CI, 0.89 to 1.14). In comparison, there was only a modest, but significant, association between quintiles of uric acid levels and progression of kidney function decrease, with adjusted odds ratios of 1.0, 0.88 (95% confidence interval, 0.64 to 1.21), 1.23 (95% CI, 0.87 to 1.75), 1.47 (95% CI, 1.04 to 2.07), and 1.49 (95% CI, 1.00 to 2.22) for quintiles 1 through 5, respectively. Higher quintiles of uric acid levels were associated with greater prevalences of estimated GFR less than 60 mL/min/1.73 m(2) (6.90 mg/dL ), respectively. Measures of kidney function were estimated GFR using the Modification of Diet in Renal Disease Study equation. Kidney disease progression was defined as a decrease in estimated glomerular filtration rate (GFR) of 3 mL/min/1.73 m(2) per year or greater (>or=0.05 mL/s) and as incident chronic kidney disease (CKD). We tested the hypothesis that uric acid may be associated with kidney disease progression.ĥ,808 participants of the Cardiovascular Health Study. Uric acid levels are increased in patients with kidney dysfunction.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |